A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection

NCT07694557 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

DRUG: YKYY025 group
DRUG: YKYY025 Placebo group

Sponsor

Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.